Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Pulmonary Medicine
Published in: BMC Pulmonary Medicine 1/2018

Open Access 01-12-2018 | Research article

Altered deposition of inhaled nanoparticles in subjects with chronic obstructive pulmonary disease

Authors: Jonas K F Jakobsson, H Laura Aaltonen, Hanna Nicklasson, Anders Gudmundsson, Jenny Rissler, Per Wollmer, Jakob Löndahl

Published in: BMC Pulmonary Medicine | Issue 1/2018

Login to get access

Abstract

Background

Respiratory tract deposition of airborne particles is a key link to understand their health impact. Experimental data are limited for vulnerable groups such as individuals with respiratory diseases. The aim of this study is to investigate the differences in lung deposition of nanoparticles in the distal lung for healthy subjects and subjects with respiratory disease.

Methods

Lung deposition of nanoparticles (50 and 100 nm) was measured after a 10 s breath-hold for three groups: healthy never-smoking subjects (n = 17), asymptomatic (active and former) smokers (n = 15) and subjects with chronic obstructive pulmonary disease (n = 16). Measurements were made at 1300 mL and 1800 mL volumetric lung depth. Each subject also underwent conventional lung function tests, including post bronchodilator FEV1, VC, and diffusing capacity for carbon monoxide, DL,CO. Patients with previously diagnosed respiratory disease underwent a CT-scan of the lungs. Particle lung deposition fraction, was compared between the groups and with conventional lung function tests.

Results

We found that the deposition fraction was significantly lower for subjects with emphysema compared to the other subjects (p = 0.001–0.01), but no significant differences were found between healthy never-smokers and smokers. Furthermore, the particle deposition correlated with pulmonary function tests, FEV1%Pred (p < 0.05), FEV1/VC%Pred (p < 0.01) and DL,CO (p < 0.0005) when all subjects were included. Furthermore, for subjects with emphysema, deposition fraction correlated strongly with DL,CO (Pearson’s r = 0.80–0.85, p < 0.002) while this correlation was not found within the other groups.

Conclusions

Lower deposition fraction was observed for emphysematous subjects and this can be explained by enlarged distal airspaces in the lungs. As expected, deposition increases for smaller particles and deeper inhalation. The observed results have implications for exposure assessment of air pollution and dosimetry of aerosol-based drug delivery of nanoparticles.
Literature
1.
Heal MR, Kumar P, Harrison RM. Particles, air quality, policy and health. Chem Soc Rev. 2012;41(19):6606–30.PubMedCrossRef
2.
Möller W, Felten K, Sommerer K, Scheuch G, Meyer G, Meyer P, Haussinger K, Kreyling WG. Deposition, retention, and translocation of ultrafine particles from the central airways and lung periphery. Am J Respir Crit Care Med. 2008;177(4):426–32.PubMedCrossRef
3.
Tarroni G, Melandri C, Prodi V, De Zaiacomo T, Formignani M, Bassi P. An indication on the biological variability of aerosol total deposition in humans. Am Ind Hyg Assoc J. 1980;41(11):826–31.PubMedCrossRef
4.
Löndahl J, Massling A, Pagels J, Swietlicki E, Vaclavik E, Loft S. Size-resolved respiratory-tract deposition of fine and ultrafine hydrophobic and hygroscopic aerosol particles during rest and exercise. Inhal Toxicol. 2007;19(2):109–16.PubMedCrossRef
5.
Heyder J, Gebhart J, Stahlhofen W, Stuck B. Biological variability of particle deposition in the human respiratory-tract during controlled and spontaneous mouth-breathing. Ann Occup Hyg. 1982;26(1–4):137–47.PubMed
6.
Rissler J, Gudmundsson A, Nicklasson H, Swietlicki E, Wollmer P, Londahl J. Deposition efficiency of inhaled particles (15-5000 nm) related to breathing pattern and lung function: an experimental study in healthy children and adults. Part Fibre Toxicol. 2017;14:10.
7.
Hofmann W, Bergmann R, Ménache MG. The effect of intersubject variability in airway morphology on intersubject variations in particle deposition. J Aerosol Sci. 1998;29(SUPPL.2):S943–4.CrossRef
8.
Hofmann W, Asgharian B, Winkler-Heila R. Modeling intersubject variability of particle deposition in human lungs. J Aerosol Sci. 2002;33(2):219–35.CrossRef
9.
Hussain M, Renate WH, Werner H. Effect of intersubject variability of extrathoracic morphometry, lung airways dimensions and respiratory parameters on particle deposition. Journal of Thoracic Disease. 2011;3(3):156–70.PubMedPubMedCentral
10.
Löndahl J, Möller W, Pagels JH, Kreyling WG, Swietlicki E, Schmid O. Measurement techniques for respiratory tract deposition of airborne nanoparticles: a critical review. J Aerosol Med Pulm Drug Deliv. 2014;27(4):229–54.
11.
Anderson PJ, Wilson JD, Hiller FC. Respiratory-tract deposition of ultrafine particles in subjects with obstructive or restrictive lung-disease. Chest. 1990;97(5):1115–20.PubMedCrossRef
12.
Brown JS, Zeman KL, Bennett WD. Ultrafine particle deposition and clearance in the healthy and obstructed lung. Am J Resp Crit Care. 2002;166(9):1240–7.CrossRef
13.
Löndahl J, Swietlicki E, Rissler J, Bengtsson A, Boman C, Blomberg A, Sandstrom T. Experimental determination of the respiratory tract deposition of diesel combustion particles in patients with chronic obstructive pulmonary disease. Part Fibre Toxicol. 2012;9:30.PubMedPubMedCentralCrossRef
14.
Aaltonen HL, Jakobsson JK, Diaz S, Zackrisson S, Piitulainen E, Londahl J, Wollmer P: Deposition of inhaled nanoparticles is reduced in subjects with COPD and correlates with the extent of emphysema: proof of concept for a novel diagnostic technique. Clin Physiol Funct Imaging 2018; doi: https://​doi.​org/​10.​1111/​cpf.​12517 .
15.
Daigle CC, Chalupa DC, Gibb FR, Morrow PE, Oberdorster G, Utell MJ, Frampton MW. Ultrafine particle deposition in humans during rest and exercise. Inhal Toxicol. 2003;15(6):539–52.PubMedCrossRef
16.
Chalupa DC, Morrow PE, Oberdorster G, Utell MJ, Frampton MW. Ultrafine particle deposition in subjects with asthma. Environ Health Perspect. 2004;112(8):879–82.PubMedPubMedCentralCrossRef
17.
Morawska L, Barron W, Hitchins J. Experimental deposition of environmental tobacco smoke submicrometer particulate matter in the human respiratory tract. Am Ind Hyg Assoc J. 1999;60(3):334–9.PubMedCrossRef
18.
Wilson FJ Jr, Hiller FC, Wilson JD, Bone RC. Quantitative deposition of ultrafine stable particles in the human respiratory tract. J Appl Physiol (1985). 1985;58(1):223–9.CrossRef
19.
Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the peripheral Airways of Young Cigarette Smokers. N Engl J Med. 1974;291(15):755–8.PubMedCrossRef
20.
Woodruff PG, Barr RG, Bleecker E, Christenson SA, Couper D, Curtis JL, Gouskova NA, Hansel NN, Hoffman EA, Kanner RE, et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med. 2016;374(19):1811–21.PubMedPubMedCentralCrossRef
21.
Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Work Group on Standardization of Respiratory Function Tests. European Community for Coal and Steel. Official position of the European Respiratory Society. Rev Mal Respir. 1994;11(Suppl 3):5–40.PubMed
22.
Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26(4):720–35.PubMedCrossRef
23.
Celli BR, MacNee W, Force AET. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–46.PubMedCrossRef
24.
Gomez FP, Rodriguez-Roisin R. Global initiative for chronic obstructive lung disease (GOLD) guidelines for chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2002;8(2):81–6.PubMedCrossRef
25.
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–38.PubMedCrossRef
26.
Bankier AA, De Maertelaer V, Keyzer C, Gevenois PA. Pulmonary emphysema: subjective visual grading versus objective quantification with macroscopic morphometry and thin-section CT densitometry 1. Radiology. 1999;211(3):851–8.PubMedCrossRef
27.
Jakobsson JKF, Hedlund J, Kumlin J, Wollmer P, Löndahl J. A new method for measuring lung deposition efficiency of airborne nanoparticles in a single breath. Sci Rep. 2016;6:36147.PubMedPubMedCentralCrossRef
28.
ICRP. Human respiratory tract model for radiological protection. A report of a task Group of the International Commission on radiological protection. Ann ICRP. 1994;24(1–3):1–482.
29.
Löndahl J, Jakobsson JKF, Broday DM, Aaltonen HL, Wollmer P. Do nanoparticles provide a new opportunity for diagnosis of distal airspace disease? Int J Nanomedicine. 2017;12:41–51.
30.
Wright JL, Lawson LM, Pare PD, Wiggs BJ, Kennedy S, Hogg JC. Morphology of peripheral airways in current smokers and ex-smokers. Am Rev Respir Dis. 1983;127(4):474–7.PubMedCrossRef
31.
Tobin MJ, Chadha TS, Jenouri G, Birch SJ, Gazeroglu HB, Sackner MA. Breathing patterns. 2. Diseased subjects. Chest. 1983;84(3):286–94.PubMedCrossRef
32.
Morrow PE, Mehrhof E, Casarett LJ, Morken DA. An experimental study of aerosol deposition in human subjects. AMA Arch Ind Health. 1958;18(4):292–8.PubMed
33.
Wiebert P, Sanchez-Crespo A, Falk R, Philipson K, Lundin A, Larsson S, Moller W, Kreyling WG, Svartengren M. No significant translocation of inhaled 35-nm carbon particles to the circulation in humans. Inhal Toxicol. 2006;18(10):741–7.PubMedCrossRef
34.
Wiebert P, Sanchez-Crespo A, Seitz J, Falk R, Philipson K, Kreyling WG, Moller W, Sommerer K, Larsson S, Svartengren M. Negligible clearance of ultrafine particles retained in healthy and affected human lungs. Eur Respir J. 2006;28(2):286–90.PubMedCrossRef
35.
Invernizzi G, Ruprecht A, De Marco C, Paredi P, Boffi R. Residual tobacco smoke: measurement of its washout time in the lung and of its contribution to environmental tobacco smoke. Tob Control. 2007;16(1):29–33.PubMedPubMedCentralCrossRef
36.
Löndahl J, Pagels J, Boman C, Swietlicki E, Massling A, Rissler J, Blomberg A, Bohgard M, Sandstrom T. Deposition of biomass combustion aerosol particles in the human respiratory tract. Inhal Toxicol. 2008;20(10):923–33.PubMedCrossRef
37.
Olvera HA, Perez D, Clague JW, Cheng YS, Li WW, Amaya MA, Burchiel SW, Berwick M, Pingitore NE: The effect of ventilation, age, and asthmatic condition on ultrafine particle deposition in children. Pulmonary Medicine 2012. https://​doi.​org/​10.​1155/​2012/​736290.
38.
Rissler J, Swietlicki E, Bengtsson A, Boman C, Pagels J, Sandstrom T, Blomberg A, Londahl J. Experimental determination of deposition of diesel exhaust particles in the human respiratory tract. J Aerosol Sci. 2012;48:18–33.CrossRef
39.
Blanchard JD, Willeke K. Total deposition of ultrafine sodium chloride particles in human lungs. J Appl Physiol Respir Environ Exerc Physiol. 1984;57(6):1850–6.PubMed
40.
Schiller CF, Gebhart J, Heyder J, Rudolf G, Stahlhofen W. Deposition of monodisperse insoluble aerosol particles in the 0.005 to 0.2 μm size range within the human respiratory tract. Annals of Occupational Hygiene. 1988;32(inhaled particles VI):41–9.
41.
Kim CS, Jaques PA. Respiratory dose of inhaled ultrafine particles in healthy adults. Philos T Roy Soc A. 2000;358(1775):2693–705.CrossRef
42.
Jaques PA, Kim CS. Measurement of total lung deposition of inhaled ultrafine particles in healthy men and women. Inhal Toxicol. 2000;12(8):715–31.PubMedCrossRef
43.
Kim CS, Jaques PA. Analysis of total respiratory deposition of inhaled ultrafine particles in adult subjects at various breathing patterns. Aerosol Sci Technol. 2004;38(6):525–40.CrossRef
44.
Blanchard JD. Aerosol bolus dispersion and aerosol-derived airway morphometry: Assessment of lung pathology and response to therapy .1. J Aerosol Med. 1996;9(2):183–205.PubMedCrossRef
45.
Blanchard JD. Aerosol bolus dispersion and aerosol-derived airway morphometry: Assessment of lung pathology and response to therapy .2. J Aerosol Med. 1996;9(4):453–76.CrossRef
46.
Lehnigk B, Schleiss M, Bluhme P, Jörres R, Brand P, Heyder J, Magnussen M. Aerosol-derived effective air space diameter (EAD) in different types of emphysema as characterized by computer tomography compared to healthy subjects. J Aerosol Med. 1995;8:126. (Abstract)
47.
Brand P, Kohlhaufl M, Meyer T, Selzer T, Heyder J, Haussinger K. Aerosol-derived airway morphometry and aerosol bolus dispersion in patients with lung fibrosis and lung emphysema. Chest. 1999;116(2):543–8.PubMedCrossRef
48.
Kohlhaufl M, Brand P, Rock C, Radons T, Scheuch C, Meyer T, Schulz H, Pfeifer KJ, Haussinger K, Heyder J. Noninvasive diagnosis of emphysema - aerosol morphometry and aerosol bolus dispersion in comparison to HRCT. Am J Resp Crit Care. 1999;160(3):913–8.CrossRef
49.
Brand P, Letzel S, Buchta M, Scheuch G, Windorfer K, Hilla W, Smith HJ, Kraus T. Can aerosol-derived airway morphometry detect early, asymptomatical lung emphysema? J Aerosol Med. 2003;16(2):143–51.PubMedCrossRef
50.
Lehnigk B, Schleiss M, Brand P, Heyder J, Magnussen H, Jorres RA. Aerosol-derived airway morphometry (ADAM) in patients with lung emphysema diagnosed by computed tomography--reproducibility, diagnostic information and modelling. Eur J Med Res. 2007;12(2):74–83.PubMed
51.
Heyder J. Gravitational deposition of aerosol particles within a system of randomly oriented tubes. J Aerosol Sci. 1975;6(2):133–7.CrossRef
52.
Heyder J. Assessment of airway geometry with inert aerosols. J Aerosol Sci. 1989;2(2):89–97.CrossRef
53.
Rosenthal FS. Aerosol recovery following breath-holding derived from the distribution of chord-lengths in pulmonary tissue. J Aerosol Sci. 1989;20(2):267–77.CrossRef
54.
Brown JH, Cook KM, Ney FG, Hatch T. Influence of particle size upon the retention of particulate matter in the human lung. Am J Public Health Nations Health. 1950;40(4):450–80.PubMedPubMedCentralCrossRef
55.
Blanchard JD, Heyder J, Odonnell CR, Brain JD. Comparison of aerosol-derived small airway caliber estimates with lung-function tests. Am Rev Respir Dis. 1986;133(4):A29.
56.
Beinert T, Brand P, Behr J, Vogelmeier C, Heyder J. Peripheral airspace dimensions in patients with COPD. Chest. 1995;108(4):998–1003.PubMedCrossRef
57.
Aaltonen HL, Kindvall S, Jakobsson JKF, Löndahl J, Olsson LE, Diaz S, Zackrisson S, Wollmer P. Airspace dimension assessment with nanoparticles reflects lung density as quantified by MRI. Int J Nanomedicine. 2018;13:2989–95.PubMedPubMedCentralCrossRef
58.
Yablonskiy DA, Sukstanskii AL, Leawoods JC, Gierada DS, Bretthorst GL, Lefrak SS, Cooper JD, Conradi MS. Quantitative in vivo assessment of lung microstructure at the alveolar level with hyperpolarized 3He diffusion MRI. Proc Natl Acad Sci. 2002;99(5):3111–6.PubMedCrossRef
Metadata
Title
Altered deposition of inhaled nanoparticles in subjects with chronic obstructive pulmonary disease
Authors
Jonas K F Jakobsson
H Laura Aaltonen
Hanna Nicklasson
Anders Gudmundsson
Jenny Rissler
Per Wollmer
Jakob Löndahl
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2018
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-018-0697-2

Other articles of this Issue 1/2018

BMC Pulmonary Medicine 1/2018 Go to the issue

Case report

Paraneoplastic syndrome as the presentation of limited stage small cell carcinoma

Research article

The effect of body position on pulmonary function: a systematic review

Research article

Higher serum 25-hydroxyvitamin D concentrations are associated with active pulmonary tuberculosis in hospitalised HIV infected patients in a low income tropical setting: a cross sectional study

Research article

Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study

Research article

Asthma exacerbations in a subtropical area and the role of respiratory viruses: a cross-sectional study

Research article

Self-reported walking and associated factors in the Spanish population with chronic obstructive pulmonary disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits